IL-17 plasma levels and psoriasis study

[Fred]

This meta-analysis evaluated IL-17 levels in patients with psoriasis. IL-17 is targeted by the new bio's:
Cosentyx (secukinumab) and Taltz (ixekizumab)

Quote:

---

Background:
Emerging evidence indicates that plasma interleukin (IL)-17 levels may be associated with increased risk of psoriasis, but the individual published results are inconclusive.

Aim:
To evaluate IL-17 levels in patients with psoriasis using a meta-analysis of studies comparing IL-17 levels in controls and in patients with psoriasis.

Methods:
All relevant studies were identified by searching pub med, Web of Science and MEDLINE databases before 1 November 2015. Pooled risk estimates were calculated by random-effects models. Crude OR and standardized mean difference (SMD) with corresponding 95% CI were also calculated.

Results:
In total, eight cross-sectional study studies were included in the final analysis. The mean plasma levels of IL-17 were higher in patients with psoriasis than in healthy controls (SMD = 0.47, 95% CI = 0.07–0.86, P < 0.001).

Conclusions:
Based on this literature review, there appears to be a positive association between IL-17 plasma levels and psoriasis.

Source: onlinelibrary.wiley.com

*Early view funding unknown.